Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 770371 + Pembrolizumab +/- Cetuximab in 1L Metastatic/Recurrent HNSCC
NCT06806852Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- May 2025
- Primary completion
- Aug 2027
- Countries
- 22
01
Overview
Phase 1, randomised, open-label trial of BI 770371 in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Objective Response up to 27 months. Started May 2025; status: active, not recruiting.
02
Drugs
BI 770371
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06806852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06806852.